BioLife Solutions, Inc.
HealthcareNASDAQ:BLFS · NASDAQ Capital Market
-$0.50 today
Vol 0.69M · Avg 0.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-3.3%
avg -32.2%
ROIC
-3.1%
avg -12.1%
ROA
-3.0%
avg -17.4%
Analysis
ROA is currently the strongest return metric at -3.0% versus its period average of -17.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Roderick de Greef | Chief Executive Officer & Chairman | $1.58M | — | 66 | $733,746.00 | 1.50% |
Troy Wichterman | Chief Financial Officer | $815,940.00 | — | 41 | $215,030.00 | 0.44% |
Aby J. Mathew | Chairman of Scientific Advisory Board, Executive Vice President & Chief Scientific Officer | $699,400.00 | — | 54 | $389,540.00 | 0.80% |
Todd Berard | Chief Commercial Officer | $695,777.00 | — | 57 | $163,412.00 | 0.33% |
Sean Werner | Chief Technology Officer | $669,600.00 | — | 52 | $48,251.00 | 0.10% |
Sarah Aebersold | Chief Human Resources Officer | — | — | 50 | $92,429.00 | 0.19% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
72
$80.60M
Net Sentiment
$80.60M
Net selling
Most Active
Foster Karen A.
11 transactions
1–10 of 72
Analysis
Insiders reported 0 buys worth $0.00 and 72 sells worth $80.60M over the last 12 months. That adds up to net selling of $80.60M. Foster Karen A. was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +4.4% | +27.3% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +4.4% over three years. Forward estimates point to Revenue at +27.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.42B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
AtriCure, Inc.
NASDAQ:ATRC
$1.46B
STAAR Surgical Company
NASDAQ:STAA
$1.41B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Phreesia, Inc.
NYSE:PHR
$560.02M
Who manages BLFS?
BioLife Solutions, Inc. (BLFS) lists 6 active executives. The top listed executive is Roderick de Greef, Chief Executive Officer & Chairman.
Are BLFS insiders buying or selling?
Recent insider activity shows net selling of $113.69M.
Explore More
Continue the stock analysis
Jump to another research area for this company.